|
|
|
|
| LEADER |
04948nam a2200553 4500 |
| 001 |
on1037351717 |
| 003 |
OCoLC |
| 005 |
20200326101153.0 |
| 006 |
m o d |
| 007 |
cr cnu---unuuu |
| 008 |
180525s2018 mau o 000 0 eng d |
| 040 |
|
|
|a N$T
|b eng
|e rda
|e pn
|c N$T
|d N$T
|d OPELS
|d EBLCP
|d YDX
|d DKU
|d OCLCF
|d UPM
|d NLE
|d UKMGB
|d D6H
|d OCLCQ
|d GrThAP
|
| 015 |
|
|
|a GBB899492
|2 bnb
|
| 016 |
7 |
|
|a 018880175
|2 Uk
|
| 019 |
|
|
|a 1038059188
|
| 020 |
|
|
|a 9780128134047
|q (electronic bk.)
|
| 020 |
|
|
|a 0128134046
|q (electronic bk.)
|
| 020 |
|
|
|a 9780128133811
|
| 020 |
|
|
|a 0128133813
|
| 035 |
|
|
|a (OCoLC)1037351717
|z (OCoLC)1038059188
|
| 050 |
|
4 |
|a RM301.3.G45
|
| 072 |
|
7 |
|a MED
|x 071000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 615.7
|2 23
|
| 245 |
0 |
0 |
|a Pharmacogenetics /
|c edited by Kim Brøsen, Per Damkier.
|
| 250 |
|
|
|a First edition.
|
| 264 |
|
1 |
|a Cambridge, MA :
|b Academic Press,
|c 2018.
|
| 300 |
|
|
|a 1 online resource
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Advances in pharmacology ;
|v volume 83
|
| 588 |
0 |
|
|a Online resource; title from PDF title page (EBSCO, viewed May 29, 2018)
|
| 505 |
0 |
|
|a Front Cover; Pharmacogenetics; Copyright; Contents; Contributors; Preface; Section I: Cytochrome P450; Chapter One: Cytochrome P450 in Pharmacogenetics: An Update; 1. Introduction; 2. Genetic Variability of CYP Enzymes; 3. CYP1A Subfamily; 3.1. CYP1A2; 4. CYP2A and CYP2B Subfamilies; 4.1. CYP2A6; 4.2. CYP2B6; 5. CYP2C Subfamily; 5.1. CYP2C8; 5.2. CYP2C9; 5.3. CYP2C19; 6. CYP2D6; 7. CYP3A Subfamily; 7.1. CYP3A4; 7.2. CYP3A5; 8. Conclusion; Conflict of Interest; References; Chapter Two: Epigenetics and MicroRNAs in Pharmacogenetics; 1. Introduction; 2. Epigenetics in Pharmacogenetics
|
| 505 |
8 |
|
|a 2.1. Polymorphisms Interacting With DMET Gene Methylation2.2. Polymorphisms Affecting Methylation Machinery; 3. miRNAs in Pharmacogenetics; 3.1. miR-SNPs Affecting Enzymes; 3.2. miR-SNPs Affecting Transporters; 3.3. miR-SNPs Affecting Regulators and miRNA Machinery; 4. Conclusion; Acknowledgments; Conflict of Interest; References; Chapter Three: Tamoxifen and CYP2D6: A Controversy in Pharmacogenetics; 1. Introduction; 1.1. Tamoxifen Metabolism; 1.2. Tamoxifen Transport; 2. CYP2D6 and Tamoxifen Metabolism; 2.1. Studies on Drug-Induced Inhibition of Tamoxifen Metabolism
|
| 505 |
8 |
|
|a 2.2. Limitations of the Pharmacoepidemiological Drug-Drug Interaction Studies2.3. Studies on Pharmacogenetically Reduced Tamoxifen Metabolism; 2.4. Comprehensive Genotyping; 2.5. Use of Tumor-Infiltrated DNA for Genotyping; 3. Perspectives; 3.1. Comprehensive Genotyping; 3.2. Genetically Reduced CYP2D6 Activity May Have Greatest Impact on Tamoxifen Effectiveness in Premenopausal Breast Canc ... ; 3.3. Tamoxifen Transport; 3.4. Other Biomarkers May Impact Tamoxifen Effectiveness; 3.5. Tamoxifen Analogues; 4. Conclusion; Acknowledgments; Conflict of Interest; References; Section II: Methods
|
| 505 |
8 |
|
|a Chapter Four: Imaging in Pharmacogenetics1. Introduction; 2. Imaging Modalities; 3. Absorption; 4. Distribution; 5. Metabolism; 6. Elimination; 7. Conclusion; Conflict of Interest; References; Chapter Five: Pharmacoepidemiology in Pharmacogenetics; 1. Introduction; 2. Study Design; 2.1. Experimental and Observational Cohort Studies; 2.1.1. Calculating Risk-Based Measures of Disease Frequency and Association; 2.1.2. Calculating Rate-Based Measures of Disease Frequency and Association; 2.2. Case-Control Studies; 2.2.1. Strategies for Sampling Controls
|
| 505 |
8 |
|
|a 2.2.2. Calculating Associations in Case-Control Studies2.3. Assessing Interaction in Epidemiologic Studies; 2.3.1. Case-Only Studies; 2.3.2. Biologic Interaction; 3. Bias and Validity; 3.1. Confounding; 3.2. Selection Bias and Matching in Case-Control Studies; 3.3. Information Bias; 3.4. Reverse Causation; 4. Conclusion; Further Reading; Conflict of Interest; References; Section III: Special Themes; Chapter Six: Population Diversity in Pharmacogenetics: A Latin American Perspective; 1. Introduction; 2. Global Distribution of PGx Variants
|
| 650 |
|
0 |
|a Pharmacogenetics.
|
| 650 |
|
0 |
|a Pharmaceutical industry
|x Technological innovations.
|
| 650 |
|
7 |
|a MEDICAL
|x Pharmacology.
|2 bisacsh
|
| 650 |
|
7 |
|a Pharmaceutical industry
|x Technological innovations.
|2 fast
|0 (OCoLC)fst01060184
|
| 650 |
|
7 |
|a Pharmacogenetics.
|2 fast
|0 (OCoLC)fst01060243
|
| 655 |
|
4 |
|a Electronic books.
|
| 700 |
1 |
|
|a Brøsen, Kim.
|
| 700 |
1 |
|
|a Damkier, Per.
|
| 776 |
0 |
8 |
|i Print version:
|t Pharmacogenetics.
|b First edition.
|d Cambridge, MA : Academic Press, 2018
|z 0128133813
|z 9780128133811
|w (OCoLC)1013515830
|
| 830 |
|
0 |
|a Advances in pharmacology (San Diego, Calif.) ;
|v 83.
|
| 856 |
4 |
0 |
|3 ScienceDirect
|u https://www.sciencedirect.com/science/bookseries/10543589/83
|z Full Text via HEAL-Link
|
| 856 |
4 |
0 |
|3 ScienceDirect
|u https://www.sciencedirect.com/science/book/9780128133811
|z Full Text via HEAL-Link
|
